Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly
The MEOPA is used to obtain an analgesia of the short-term painful acts. To the population of elderly patients, the therapeutic resources to control the passing pain require in their manipulation a certain caution and are not divested of side effects badly tolerated at this age. An alternative in the opioid presents all its interest. The MEOPA is here an alternative of choice in the care of these pains, in particular in case of pre-existent cognitive achievement, of polypathologies or of polymédication.
The gas MEOPA administered to the mask could thus be an effective additive in the physiotherapy treatment of the elderly person.
The main objective is to Assess the efficacy , in terms of recovery of the hip and knee joint articular amplitude, of 3 sessions of reeducation using MEOPA versus standard reeducation within a population of elderly patients presenting a pain during the physiotherapy treatment.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Nice, France
- CHU de Nice
-
Nice, France, 06000
- Pôle de Gérontologie Hôpital de Cimiez CHU de Nice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged 65 years old or more
- Patients having a prescription for physiotherapy
- Absence of contraindication to MEOPA
- Patients whose initial assessment show a passive articular deficit of at least a joint of hip or the knee and whose painful assessment is ≥ 5 or ≥ 2 during mobilisation on the validated scale Algoplus
- Patients whose reeducation project established by the physiotherapist
- Patients having agreed to participate in the study and having signed the consent
- Subjects affiliated to the social security system
Exclusion Criteria:
- Patient requiring a ventilation in pure oxygen
- Patient with a consciousness deterioration preventing his cooperation
- Care under MEOPA during the period of the protocol and during the month which precedes
- Increase of the dosage of morphine of less than 48 hours Patient under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MEOPA
ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
|
3 sessions of reeducation using MEOPA
|
|
No Intervention: Without MEOPA
Physiotherapit care without MEOPA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
% of recovery of the hip and knee joint articular amplitude
Time Frame: 5 days
|
% of recovery of the hip and knee joint articular amplitude during 5 days after 3 sessions of reeducation using MEOPA versus standard reeducation within a population of elderly patients presenting a pain during the physiotherapy treatment; measure % of recovery of the hip and knee joint articular amplitude two times : before the beginning of the session of reeducation and at the end of the session
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure of the pain
Time Frame: 5 days
|
Patient answer a questionnaire on his pain at the beginning of each session of reeducation (5 sessions)
|
5 days
|
|
Patients'satisfaction
Time Frame: End of the period of care (up to 5 days)
|
Patient answer a questionnaire on this satisfaction at the end of the period of care of the protocol.
|
End of the period of care (up to 5 days)
|
|
Physiotherapists'satisfaction
Time Frame: End of all the period of care (up to 5 days)
|
Physiotherapists answer a questionnaire on this satisfaction of the use of the MEOPA
|
End of all the period of care (up to 5 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Véronique Mailland, MD, Centre Hospitalier Universitaire de Nice
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-000065-37
- 12AOI02 (Other Identifier: CHU DE NICE)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.